CriticalAntidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)×Antidepressant (other antidepressants, N06AX)
Updated · Methodology
Mechanism
Phenelzine is a potent, non-selective inhibitor of monoamine oxidase (MAO) (phenelzine label, US Food and Drug Administration, FDA). Vortioxetine inhibits the serotonin transporter and acts on serotonin receptors, and its risk of serotonin syndrome rises with drugs that affect serotonin metabolism, MAO inhibitors included (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). MAO inhibitors impair serotonin metabolism and, together with serotonergic antidepressants such as vortioxetine, raise the risk of life-threatening serotonin syndrome (vortioxetine FDA label). The elimination half-life of vortioxetine is 66 hours (vortioxetine SmPC, EMA).
Symptoms
Severe reactions, including hyperthermia, muscle rigidity, myoclonus and death, have been reported when serotonergic drugs were combined with a monoamine oxidase inhibitor (phenelzine label, US Food and Drug Administration, FDA). Serotonin syndrome shows as changes in consciousness (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high body temperature), neuromuscular problems (overactive reflexes, poor coordination) and nausea, vomiting or diarrhoea, and it can be life-threatening (vortioxetine summary of product characteristics, SmPC, European Medicines Agency, EMA). With monoamine oxidase inhibitors, vortioxetine also carries a higher risk of neuroleptic malignant syndrome (vortioxetine SmPC, EMA). The US vortioxetine label adds tremor and seizures (vortioxetine FDA label).
Management
The combination is contraindicated. The EU vortioxetine summary of product characteristics (SmPC) contraindicates it with non-selective monoamine oxidase inhibitors (MAOIs), the group phenelzine belongs to (vortioxetine SmPC, European Medicines Agency, EMA). The US vortioxetine label names phenelzine among contraindicated MAOIs, and the US phenelzine label contraindicates phenelzine with serotonergic drugs (vortioxetine and phenelzine labels, US Food and Drug Administration, FDA). Phenelzine is not authorised in Spain and has no Spanish SmPC. Start vortioxetine at least 14 days after stopping phenelzine (vortioxetine FDA label; vortioxetine SmPC, EMA, for irreversible non-selective MAOIs). Start phenelzine at least 21 days after stopping vortioxetine under the US vortioxetine label (FDA), or at least 14 days under the EU SmPC (EMA). The US phenelzine label says to wait until the serotonergic drug has cleared (phenelzine FDA label). If signs of serotonin syndrome appear, stop vortioxetine and other serotonergic drugs at once and start supportive symptomatic treatment (vortioxetine SmPC, EMA, and FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.4 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, información del producto actualizada 19/01/2026, secciones 4.3, 4.4, 4.5 y 5.1
- EMA: Ficha técnica: Vortioxetina – Brintellix (EU/1/13/891), sección 4.3 (2026)– EMA, SmPC Brintellix (EU/1/13/891), texto en CIMA nº 113891010, consultado 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.5 y 5.2
- FDA: TRINTELLIX (vortioxetine) tablets prescribing information (Takeda) (2025)– FDA, DailyMed setid 1a5b68e2-14d0-419d-9ec6-1ca97145e838 (Takeda Pharmaceuticals America), revisión 02/2025 (versión 18, vigente desde 05.03.2025), secciones 2.4, 4, 5.2 y 7.1